Study to Assess Platelet Dysfunction With Verify Now Assay

Platelet Aggregation Defects Clinical Trial

Official title:

"In-vitro Characterization of Platelet Dysfunction in Common Hematological Disorders Using the Verify Now Assay"

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01167218
• Other study ID #: 09318
• Status: Completed
• Start date: December 2009
• Est. completion date: February 2012

Study information

• Verified date: February 2019
• Source: New York University School of Medicine
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to conduct a Verify now assay to detect platelet aggregation defects in patients with Myelodysplastic syndrome(MDS), immune thrombocytopenia purpura (ITP) and myeloproliferative disorders (MPD).

Description:

Verify Now is a rapid, simple, point-of service assay to measure platelet aggregation. The verify now assay is designed to assess platelet function based on the ability of activated platelets to bind fibrinogen. It is hoped that this study will detect the subtle platelet functional abnormalities in patients with hematological disorders.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 79
• Est. completion date: February 2012
• Est. primary completion date: February 2012
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria

• Patients with common blood disorders such as immune thrombocytopenia purpura(ITP) myelodysplastic syndrome MDS)and myeloproliferative disorders (MPV)

Exclusion Criteria

• Patients with normal platelet counts

Related Conditions & MeSH terms

• Hematologic Diseases
• Platelet Aggregation Defects

Locations

Country	Name	City	State
United States	Winthrop University Hospital Oncology/Hematology Division	Mineola	New York

Sponsors (1)

Lead Sponsor	Collaborator
New York University School of Medicine

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	platelet aggregation defects	to assess platelet aggregation defects	one year